Open Orphan reported its full-year results to 31 December (FY20) this morning. The group reported revenues and other income of £22m in 2020 with operating loss before exceptionals of £8.3m, slightly below expectations due to the phasing of costs through H2 2020. 2021 has started well and industry activity around COVID and respiratory disease provides a wealth of opportunity and 2021 catalysts.
17 Jun 2021
Open Orphan* - Broad Opportunity Set - Buy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan* - Broad Opportunity Set - Buy
hVIVO plc (HVO:LON) | 29.0 0 0.0% | Mkt Cap: 197.3m
- Published:
17 Jun 2021 -
Author:
Andrew Simms | Philip Modu -
Pages:
7
Open Orphan reported its full-year results to 31 December (FY20) this morning. The group reported revenues and other income of £22m in 2020 with operating loss before exceptionals of £8.3m, slightly below expectations due to the phasing of costs through H2 2020. 2021 has started well and industry activity around COVID and respiratory disease provides a wealth of opportunity and 2021 catalysts.